近一年来，中国药企在国际舞台上频频亮相，国际社会对中国制药业的发展关注度持续攀升。 一方面，融资层面寒意未消。数据显示，2025年上半年中国创新药公司完成134起融资，数量为近10年同期最低；一级市场公开交易笔数与总 金额呈逐月下降趋势。另一方面，海外授权交易热潮涌动，商业拓展（BD）交易空前活跃，成为替代融资的"造血"生命线。 2026年的医药市场究竟会呈现怎样的态势？ 毛化。资料图 过去一年，中国生物科技企业的股价涨幅远超美国同类企业，这一切无不表明，全球生物医药创新长达一个世纪的"西方主导"格局正悄然改 变。 不过，谈及市场周期，沙利文大中华区合伙人兼董事总经理毛化在接受21世纪经济报道专访时，以"分化与修复并存"概括当下态势。 "中国创新药行业已逐步走出底部，进入修复与分化并存的新阶段。"毛化指出，尽管当下医药市场有所回暖，但周期是否"彻底结束"仍需理性 看待。 这一判断的背景是：2025年以来，创新药出海交易数据屡创新高，但资本寒冬的印记仍深，市场"冷热不均"的特征十分显著。 拐点、重塑 2025年以来，创新药出海加快、一级市场融资回暖、海外基石投资者重返港股IPO，行业投融资活跃度显著提升。当被问 ...

Core Insights - The innovative pharmaceutical sector is transitioning from narrative to realization, with the total amount of License out expected to exceed $120 billion by 2025 [1] - Policy support for innovative drugs is comprehensive, introducing a dual payment system with commercial insurance and medical insurance [1] - The medical device sector is stabilizing, with high-value consumables and medical equipment showing signs of recovery, and domestic production rates surpassing 87% [1] Group 1: Pharmaceutical Industry - The innovative drug sector is entering a phase where the narrative is being realized, with projections indicating that License out amounts will exceed $120 billion by 2025 [1] - The introduction of a dual payment system for innovative drugs, combining commercial insurance with medical insurance, marks a significant policy shift [1] - The raw material drug sector is at a cyclical low, with most prices stabilizing, and the arrival of the "patent cliff" is expected to create growth opportunities for generic drugs and associated APIs [1] Group 2: Medical Devices and Diagnostics - The medical device sector is experiencing a gradual clearing of policy disruptions, with high-value consumables and medical equipment leading the recovery [1] - The domestic production rate for medical devices has exceeded 87%, indicating a strong trend towards localization [1] - Improvements in the in-vitro diagnostics and low-value consumables sectors are anticipated by 2026 [1] Group 3: Consumer Healthcare - The consumer healthcare sector, including traditional Chinese medicine and biological products, is expected to gradually recover from its low point [1] Group 4: AI and Healthcare - The AI in healthcare sector is seeing a surge in policy announcements, with brain-computer interfaces being highlighted as a key industry in the 14th Five-Year Plan, accelerating the commercialization of non-invasive products [1] Group 5: Investment Products - The Guotai Innovation Pharmaceutical ETF (159377) tracks the Innovation Pharmaceutical Index (399275), which has a daily fluctuation of 20%, focusing on companies with high R&D investment and innovation capabilities [1]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with significant trading activity and price increases among leading innovative drug companies, indicating a shift in the market dynamics for innovative pharmaceuticals in China [1][3]. Group 1: Market Performance - On December 23, the Hong Kong Stock Connect innovative drug ETF (520880) reached a peak increase of 1.53% and recorded over 1.4 billion yuan in trading volume [1]. - Leading companies in the innovative drug sector, such as CSPC Pharmaceutical Group, saw stock price increases exceeding 5%, while others like 3SBio and Hengrui Medicine rose over 2% [1]. Group 2: Investment Insights - Analysts from Zhongtai Securities noted that the current innovative drug market differs from the 2019-2021 period, as it has transitioned from narrative to actual performance, with trading volumes hitting new highs, reflecting a leap in China's innovative capabilities [1]. - Changjiang Securities emphasized that the innovative drug sector is entering a new cycle of policy support, suggesting a focus on high-quality innovative drug assets with strong overseas potential [3]. Group 3: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: it exclusively includes innovative drug companies, has a high concentration of leading firms (over 72% in the top ten), and employs measures to control risks associated with less liquid stocks [3][4]. - The ETF's current market price is close to its initial listing price, presenting a potential value opportunity for investors [3]. Group 4: Composition and Strategy - The top ten holdings of the Hong Kong Stock Connect innovative drug ETF account for 72.57% of the total weight, showcasing significant dominance by leading companies in the sector [4]. - For investors seeking to mitigate volatility while still focusing on innovative drugs, alternative ETFs that include a mix of traditional Chinese medicine and innovative drugs are available, providing a balanced investment approach [4].

Group 1 - The core viewpoint of the report is that the recent pullback in the pharmaceutical sector is primarily due to the digestion and rebalancing of valuations and expectations, which creates a better investment window for future opportunities [1] - Looking ahead to 2026, the trend of innovative drugs going overseas is expected to continue, with a focus on the clinical progress and data validation of pipelines that have already entered international markets [1] - The impact of the recently signed U.S. Biosecurity Act on Chinese CXO companies is anticipated to be limited, as it does not affect Medicaid and Medicare procurement and has clear definitions regarding related parties, along with the relatively small revenue contribution from U.S. administrative agencies to Chinese CXO firms [1] Group 2 - The industry outlook suggests a more conservative investment approach, emphasizing opportunities in undervalued stocks [1] - Recommended stocks for investment include 3SBio, Genscript Biotech, WuXi AppTec, and China National Pharmaceutical Group [1]

Group 1 - The Hong Kong pharmaceutical sector showed a quick recovery after a slight dip, with companies like CSPC Pharmaceutical, 3SBio, Rongchang Biopharmaceutical, and Hengrui Medicine leading the gains [1] - The Hong Kong Innovative Drug ETF (159567) rose by 1.27% as of 9:59 AM, indicating a potential for a three-day winning streak, with a trading volume exceeding 290 million yuan [1] - Since the beginning of this month, the product's shares have increased by 58.7 million, with a cumulative net inflow of over 480 million yuan [1] Group 2 - The current innovative drug market differs from the period of 2019-2021, as the narrative of Chinese innovative drugs going global has transitioned into a phase of actual realization, with transaction amounts reaching new highs [1] - This reflects a leap in China's innovation capability from "quantity" to "quality," supported by continuous domestic policy initiatives that comprehensively back innovative drugs, including the introduction of a commercial insurance directory [1] - The Hong Kong Innovative Drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, aiming to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [1]

Group 1 - The core viewpoint of the article highlights that the Chinese innovative pharmaceutical industry is transitioning from "transaction heat" to "value realization," with a total licensing transaction amount exceeding $92 billion in the first three quarters of 2025 [1][2] - The first edition of the "Commercial Health Insurance Innovative Drug Directory" was officially released in December, establishing a multi-layered payment system that opens new market pathways for high-value innovative drugs [1][6] - The industry is expected to see a surge in innovative drug business development (BD) activities, supported by favorable policies and the dual push of commercial insurance implementation and procurement optimization [1][2][3] Group 2 - In the first half of 2025, the total amount of license-out transactions for Chinese innovative drugs approached $66 billion, surpassing the total amount for 2024, which was $51.9 billion, marking a historical high [2] - Significant transactions include a $12.5 billion upfront payment from 3SBio to Pfizer for exclusive global rights to a self-developed PD-1/VEGF bispecific antibody, and a strategic cooperation agreement between Hengrui Medicine and GlaxoSmithKline potentially worth up to $12 billion [2][3] - The release of the commercial health insurance directory and the dynamic adjustment of the national medical insurance directory are seen as crucial steps in creating a multi-layered payment system that alleviates the payment challenges for high-value innovative drugs [6][7] Group 3 - The past year has seen a surge in innovative drug exports, driven by policy support, capital influx, talent, and innovative business models [3] - The "NewCo" model, where investment funds lead the establishment of new companies, allows local pharmaceutical companies to license overseas rights while gaining equity, facilitating large transactions [3] - The successful value realization cases are expected to enhance international buyers' trust in the delivery capabilities of Chinese biotech, creating a positive cycle of high-value transactions [4][5] Group 4 - The comprehensive reforms in the pharmaceutical sector over the past decade have laid the groundwork for the current wave of innovative drug exports, with significant policy breakthroughs expected to further enhance the industry's global competitiveness [6][8] - The establishment of a complete closed-loop system from research and development to international multi-center clinical trials indicates a more mature future for the innovative drug industry [8]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index and the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index both fell by 0.8%, while the CSI Biotechnology Theme Index decreased by 0.4%, and the CSI Innovative Drug Industry Index and the CSI 300 Pharmaceutical and Health Index both declined by 0.3% [1][10][16] - Despite the overall market decline, the Hang Seng Innovative Drug ETF (159316) saw a net subscription of 22 million units throughout the day, indicating strong investor interest [1] - According to Zhongtai Securities, the current innovative drug market differs from the 2019-2021 period, as the narrative around innovative drugs has transitioned into a phase of actual realization, with transaction amounts reaching new highs, reflecting a leap in China's innovative capabilities from "quantity" to "quality" [1][3] Group 2 - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index focuses on leading companies in the Hong Kong medical and health industry, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other health sectors [4] - The CSI Innovative Drug Industry Index tracks leading A-share innovative drug companies, consisting of no more than 50 stocks involved in innovative drug research and development [6] - The CSI 300 Pharmaceutical and Health Index covers leading companies in the A-share pharmaceutical and health sector, including chemical pharmaceuticals, medical services, and medical devices, representing various segments of the future health industry [14]

Core Insights - Chinese innovative pharmaceutical companies are making significant strides in global expansion, as evidenced by the simultaneous announcements from Qianxin Biopharma and Xiansheng Pharmaceutical regarding their licensing agreements with international partners, totaling up to $1.76 billion [1][3]. Group 1: Licensing Agreements - Qianxin Biopharma has licensed its self-developed drug QX027N, a long-acting dual-specific antibody targeting TSLP and IL-13, to Windward Bio Group AG's subsidiary LE2025 Therapeutics AG, with a total potential consideration of up to $700 million, including upfront payments, equity, development, and commercial milestone payments, plus tiered royalties [1][9]. - Xiansheng Pharmaceutical's subsidiary Jiangsu Xiansheng Zaiming Pharmaceutical Co., Ltd. has reached an agreement with Ipsen Pharma SAS to license the global rights (excluding Greater China) for the antibody-drug conjugate SIM0613 targeting LRRC15, with a total transaction value of up to $1.06 billion, including a $45 million upfront payment and subsequent milestone payments [1][9]. Group 2: Drug Profiles - QX027N is designed to target two immune pathways, TSLP and IL-13, which are critical in allergic and inflammatory diseases, potentially offering superior efficacy in treating asthma and atopic dermatitis. The long-acting design aims to reduce dosing frequency and improve patient compliance, which is a key consideration for Windward Bio [3][11]. - SIM0613 is a novel ADC targeting LRRC15, which is highly expressed in various solid tumors and tumor-associated fibroblasts but minimally expressed in normal cells. The ADC technology combines antibody targeting with the cytotoxicity of chemotherapy agents, representing a significant direction in cancer treatment [2][5][13]. Group 3: Industry Implications - The announcements reflect a maturation of the Chinese pharmaceutical industry, showcasing its ability to participate in global competition with high-quality and diversified innovative drugs. The successful licensing of these drugs marks a pivotal moment for the industry as more Chinese-developed innovative drugs enter the global market, reshaping the global pharmaceutical landscape [7][14].

Investment Rating - The report assigns an investment rating of "Outperform the Market" for the pharmaceutical sector, indicating a relative performance better than the benchmark index [8]. Core Insights - The pharmaceutical sector has shown resilience, with the SW Pharmaceutical Bio Index declining only 0.14% compared to the Shanghai and Shenzhen 300 Index's decline of 0.28% during the week of December 15-21 [2]. - The report highlights significant developments in AI healthcare, particularly with the launch of Ant Group's upgraded AI health app "Antifufu," which aims to enhance health management for users [2]. - Insilico Medicine's IPO is anticipated to drive innovation in drug development, with a focus on its AI-driven platform Pharma.AI and promising clinical results for its lead product Rentosertib [2]. - The approval of the Enhertu and trastuzumab combination therapy for HER2-positive breast cancer is expected to redefine first-line treatment standards in this area [2]. - The report emphasizes the potential of Chinese innovative drugs in international markets and suggests continued monitoring of key sectors such as ADCs, bispecific antibodies, and weight-loss drugs [2]. Summary by Sections Industry Performance - The pharmaceutical sector's weekly trading volume was 389.82 billion yuan, showing a slight decline compared to previous weeks, indicating a need for recovery in market sentiment [2]. AI Healthcare Developments - The "Antifufu" app connects users with 300,000 real doctors for online consultations and has over 15 million monthly active users, with 55% from lower-tier cities, showcasing the app's broad reach [2]. IPO and Drug Development - Insilico Medicine's IPO is set for December 30, with a total fundraising target of 2.277 billion HKD, primarily for clinical research of its drug pipeline [2][5]. Treatment Innovations - The Enhertu and trastuzumab combination therapy has shown a significant improvement in progression-free survival rates, marking a major advancement in treatment options for HER2-positive breast cancer [2].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The trend of Chinese innovative drugs going overseas is opening up long-term value for companies, with significant collaborations occurring since September 2025. The innovative drug index has decreased by 11.34% from September 1 to December 19, underperforming the CSI 300 index by 12.93 percentage points. However, the index has increased by 38.65% since the beginning of the year, outperforming the CSI 300 index by 20.76 percentage points [2] - The report emphasizes the importance of oral immunomodulatory drugs, highlighting the positive results from Takeda's TYK2 inhibitor, zasocitinib, in treating moderate to severe plaque psoriasis. This drug is expected to provide significant benefits to patients and is part of a broader trend of domestic companies developing oral immunomodulatory drugs [3] - The report notes the progress of domestic small nucleic acid drugs, with YKYY032 receiving clinical approval from both the FDA and NMPA. The report anticipates an increase in clinical approvals for small nucleic acid drugs by 2026, as more companies enter this field [5] - The report tracks the flu season, indicating a peak in flu cases and a corresponding increase in the use of new flu medications, which are expected to see significant sales growth due to improved treatment protocols and online sales [7] - The report highlights a recovery in the financing of domestic innovative drugs, with a total financing amount of $5.51 billion in the first three quarters of 2025, a 67.6% increase year-on-year. The report also notes a significant increase in orders for CXO companies, indicating a positive trend in the industry [8] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.14 percentage points in the last week, ranking 22nd among 31 sectors [20] - Over the past month, the pharmaceutical industry underperformed the CSI 300 index by 2.06 percentage points, ranking 19th [24] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has decreased by 2.50% over the past month, underperforming the CSI 300 index by 2.06 percentage points [40] - The current PE (TTM) for the pharmaceutical industry index is 37.07, above the five-year historical average of 31.16 [44] 3. Recent Research Achievements - The report includes various deep-dive studies on the pharmaceutical industry, focusing on topics such as the growth of oral drugs and the stability of blood products [48] 4. Recent Industry Policies and News - Recent policies from the National Healthcare Security Administration aim to improve the quality and efficiency of medical insurance fund settlements, which could positively impact the pharmaceutical sector [50] - Significant news includes the approval of new drugs by various companies, indicating ongoing innovation and development within the industry [51][52]